阿托伐他汀在慢性阻塞性肺疾病中的治疗作用探讨  

Effect analysis of atorvastatin in chronic obstructive pulmonary disease

作　　者：王浩凌[1] 赖成毅 

机构地区：[1]四川省攀枝花市中心医院,617067

出　　处：《临床合理用药杂志》2011年第23期11-12,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨阿托伐他汀在慢性阻塞性肺疾病(COPD)中的治疗作用。方法将50例COPD患者随机分为治疗组和对照组各25例。对照组给予常规治疗,治疗组在对照组治疗基础上给予阿托伐他汀治疗。1个月后比较2组肺功能变化情况,包括第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)及FEV1占预计值(%),并观察2组疗效。结果治疗组总有效率为96%高于对照组的84%,差异有统计学意义(P<0.05)。2组治疗后FEV1、FEV1/FVC及FEV1占预计值均升高,差异均有统计学意义(P<0.05),且治疗组改善情况优于对照组,差异均有统计学意义(P<0.05)。结论他汀类药物可能在慢性阻塞性肺疾病的病理生理进程中产生有利的影响,改善肺功能及COPD患者的生活质量。Objective To observe the effect of atorvastatin in chronic obstructive pulmonary disease（COPD）. Methods 50 Cases patients with COPD were randomly divided into treatment group and control group, each of 25 cases. Control group received conventional therapy, treatment group were given with atorvastatin on the basis of atorvastatin treatment. 1 month after pulmonary function changes,including forced expiratory volume （FEV1）, FEV1/FVC and FEV1 percentage of predicted value（ % ）in both groups were compared, and the effect was observed. Results After treatment, FEV,, FEV1/FVC and FEV, percentage of predicted value in both groups were increased, the difference were statistically significant（ P 〈 0.05 ）, and the improvement of treatment group were better than those in control group （ P 〈 0.05 ）. The total effective rate of treatment group （96%） was higher than that of control group（84% ） （P 〈 0.05）. Conclusion Statins may be beneficial effect on the pathophysiology process in COPD, and improve pulmonary function and quality of life of patients with COPD.

关 键 词：阿托伐他汀 肺疾病 慢性 阻塞性 肺功能 气道炎症 

分 类 号：R563.9[医药卫生—呼吸系统]